286 related articles for article (PubMed ID: 30027936)
41. Clinicopathological Characteristics of Gastroenteropancreatic Neuroendocrine Tumors: 10 Years of Experience From a Single Center.
Şentürk M; Acar B; Yildirim MA; Çakir M; Küçükkartallar T; Vatansev C
Pancreas; 2022 Feb; 51(2):159-163. PubMed ID: 35404891
[TBL] [Abstract][Full Text] [Related]
42. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
[TBL] [Abstract][Full Text] [Related]
43. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
44. Assessing the Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine Tumors.
Yang JY; Baeg K; Martin JA; Wisnivesky J; Kim MK
Pancreas; 2021 Nov-Dec 01; 50(10):e81-e82. PubMed ID: 35041348
[No Abstract] [Full Text] [Related]
45. Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia.
Marasco M; Magi L; Rogges E; Dell'Unto E; Rinzivillo M; Pilozzi E; Annibale B; Panzuto F
Endocrine; 2023 Nov; 82(2):435-441. PubMed ID: 37338723
[TBL] [Abstract][Full Text] [Related]
46. Expression of Stem Cell-associated Marker HES77 in Rectal Neuroendocrine Tumors.
Jernman J; Hagström J; Mäenpää H; Välimäki MJ; Haapasalo H; Nilsson O; Fermér C; Haglund C; Arola J
Anticancer Res; 2015 Jul; 35(7):3767-72. PubMed ID: 26124320
[TBL] [Abstract][Full Text] [Related]
47. [Interpretation and evaluation of the American Joint committee on Cancer (AJCC) 8th Edition Staging System for patients with gastroenteropancreatic neuroendocrine tumors].
Chen L; Zhou Z; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):972-976. PubMed ID: 28900985
[TBL] [Abstract][Full Text] [Related]
48. [Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014?].
Scoazec JY; Couvelard A;
Ann Pathol; 2014 Feb; 34(1):40-50. PubMed ID: 24630636
[TBL] [Abstract][Full Text] [Related]
49. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
Aoki T; Kokudo N
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
[No Abstract] [Full Text] [Related]
50. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients.
Nguyen AH; O'Leary MP; De Andrade JP; Ituarte PG; Warner SG; Melstrom LG; Kessler J; Fong Y; Li D; Singh G
Am J Surg; 2022 May; 223(5):939-944. PubMed ID: 34474917
[TBL] [Abstract][Full Text] [Related]
51. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
Pusceddu S; Buzzoni R; De Braud F
Ann Oncol; 2013 May; 24(5):1415-6. PubMed ID: 23493138
[No Abstract] [Full Text] [Related]
52. [Difficulties and challenges in pathological diagnosis of gastrointestinal pancreatic neuroendocrine tumors].
Luo J; Shi YF
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):996-999. PubMed ID: 35399018
[TBL] [Abstract][Full Text] [Related]
53. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations.
Kahraman S; Bardakci M; Aykan MB; Yasar S; Erol C; Hizal M; Akinci MB; Kos FT; Kos T; Dede DS; Karadurmus N; Yalcin S; N Sendur MA; Yalcin B
J Cancer Res Ther; 2023; 19(2):347-354. PubMed ID: 37006071
[TBL] [Abstract][Full Text] [Related]
54. Imaging of secretory tumors of the gastrointestinal tract.
ElGuindy YM; Javadi S; Menias CO; Jensen CT; Elsamaloty H; Elsayes KM
Abdom Radiol (NY); 2017 Apr; 42(4):1113-1131. PubMed ID: 27878636
[TBL] [Abstract][Full Text] [Related]
55. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
de Herder WW
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):689-90. PubMed ID: 23582912
[No Abstract] [Full Text] [Related]
56. Classification of neuroendocrine tumors.
Klöppel G
Verh Dtsch Ges Pathol; 1997; 81():111-7. PubMed ID: 9474861
[TBL] [Abstract][Full Text] [Related]
57. Recommended parameters for pathology reporting of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Malays J Pathol; 2018 Apr; 40(1):79-82. PubMed ID: 29704389
[TBL] [Abstract][Full Text] [Related]
58. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
59. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract][Full Text] [Related]
60. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
